Skip to content
DataLookout
Start free
Menu

NCT06581861

PREVENT ALL ALS Study

StatusActive, Not Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 15 with changes below. See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 1 of 6 entries
    • Site details revised at 32 of 32 sites
  2. Site contacts updated at 1 of 32 sitesv14
  3. Site contacts updated at 2 of 32 sitesv13
  4. Site contacts updated at 2 of 32 sitesv12
  5. Site contacts updated at 27 of 32 sitesv11
Show 9 earlier versionsHide 9 earlier versions
  1. Site contacts updated at 6 of 32 sitesv10
  2. Study sites: 27 to 32v9
  3. Study sites: 22 to 27v8
  4. Study sites: 18 to 22v7
  5. Study sites: 17 to 18v6
  6. Study sites: 15 to 17v5
  7. Study sites: 12 to 15v4
  8. Study sites: 8 to 12v3
  9. Study sites: 3 to 8v2
  1. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

ALS Symptoms Questionnaire
Timeframe: Baseline, 4, 8, 12,16,20, 24, 28, 32 and 36 months form baseline

Secondary (6)

Environmental History
Cognitive assessment (ECAS)
Cognitive assessment (CDR-FTLD)
Hand-Held Dynamometry (HHD)
Digital Speech Assessment
Show 1 moreShow less
Vital Capacity (VC)

Sites

32 sites in 2 countries

United States 31, Puerto Rico 1